Merck Dirección
Dirección controles de criterios 3/4
El CEO de Merck es Rob Davis , nombrado en Apr 2021, tiene una permanencia de 5.08 años. compensación anual total es $20.80M, compuesta por 7.9% salario y 92.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.018% de las acciones de la empresa, por valor de $49.75M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 6.7 años, respectivamente.
Información clave
Rob Davis
Chief Executive Officer (CEO)
US$20.8m
Compensación total
| Porcentaje del salario del CEO | 7.91% |
| Permanencia del CEO | 5.1yrs |
| Participación del CEO | 0.02% |
| Permanencia media de la dirección | 5.3yrs |
| Promedio de permanencia en la Junta Directiva | 6.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Merck: Bullish Setup Into Q1 Earnings
Apr 27
Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)
Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.
MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple
Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.
MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside
Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple
The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside
Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.
MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance
Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple
Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.
The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff
Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance
Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes
Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.MRK: Cidara Flu Deal Will Likely Expose Overstated Long Term Expectations
Analysts have nudged their fair value estimate for Merck higher, lifting the price target by $1 to $83 as they factor in stronger revenue growth, improved profit margins, and a lower future P/E multiple supported by recent positive research initiations and deal activity. Analyst Commentary Street research around Merck has turned more constructive in recent weeks, with several firms highlighting an improving growth outlook and a more attractive risk reward profile.Merck predicts unstoppable growth with KEYTRUDA and WINREVAIR hitting record hihs
based on Q3 resultMRK: Cidara Acquisition And Patent Overhang Will Shape Future Risk Reward Balance
Analysts have modestly raised their fair value estimate for Merck to approximately $106.62 from about $104.27 per share, citing the higher Street price target of $105, growing confidence in its infectious disease and oncology pipeline, and the view that shares remain attractively valued relative to the company's long term growth prospects. Analyst Commentary Street research on Merck continues to highlight a constructive long term outlook balanced by execution and concentration risks, with recent notes refining expectations around valuation, pipeline durability, and capital allocation.Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85
Dec 02
MRK: Recent Pipeline Deals And Patent Expiry Will Shape Outlook Ahead
Analysts have raised the price target for Merck to $105 from $98, citing stronger growth prospects and a more favorable valuation because of the company’s expanding pipeline and recent strategic deals. Analyst Commentary Recent analyst commentary on Merck highlights both positive momentum and notable risks that could influence the company’s trajectory in the months ahead.Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 02US Investments And New Product Launches Will Shape Future Markets
Merck’s analyst price target edged up to $101.75, driven by positive sentiment around the Verona Pharma acquisition’s boost to the respiratory portfolio, ongoing digital and oncology partnerships, and stable vaccine outlook. Analyst Commentary Bullish analysts point to Merck’s $10B acquisition of Verona Pharma, seeing Verona’s Ohtu as a strategic anchor drug to expand Merck’s respiratory franchise and enhance competitiveness against major therapeutics in the space.Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$9b |
| Dec 31 2025 | US$21m | US$2m | US$18b |
| Sep 30 2025 | n/a | n/a | US$19b |
| Jun 30 2025 | n/a | n/a | US$16b |
| Mar 31 2025 | n/a | n/a | US$17b |
| Dec 31 2024 | US$23m | US$2m | US$17b |
| Sep 30 2024 | n/a | n/a | US$12b |
| Jun 30 2024 | n/a | n/a | US$14b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$20m | US$2m | US$365m |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$13b |
| Dec 31 2022 | US$19m | US$2m | US$15b |
| Sep 30 2022 | n/a | n/a | US$15b |
| Jun 30 2022 | n/a | n/a | US$17b |
| Mar 31 2022 | n/a | n/a | US$14b |
| Dec 31 2021 | US$14m | US$1m | US$12b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$7m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$9b |
| Jun 30 2020 | n/a | n/a | US$9b |
| Mar 31 2020 | n/a | n/a | US$9b |
| Dec 31 2019 | US$8m | US$1m | US$6b |
Compensación vs. Mercado: La compensación total de Rob($USD20.80M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD14.60M).
Compensación vs. Ingresos: La compensación de Rob ha sido consistente con los resultados de la empresa en el último año.
CEO
Rob Davis (58 yo)
5.1yrs
Permanencia
US$20,797,845
Compensación
Mr. Robert M. Davis, also known as Rob, J.D., is CEO and Director of Merck Sharp & Dohme LLC since July 1, 2021 and has been its Chairman since December 1, 2022. He is Chief Executive Officer and Director...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 5.1yrs | US$20.80m | 0.018% $ 49.8m | |
| Executive VP & CFO | 5.1yrs | US$7.51m | 0.0037% $ 10.1m | |
| Executive VP & General Counsel | 8.1yrs | US$5.86m | 0.0028% $ 7.7m | |
| Executive VP & President of Merck Manufacturing Division | 16.5yrs | US$5.41m | 0.0081% $ 22.4m | |
| Executive VP & President of Merck Research Laboratories | 8.5yrs | US$8.89m | 0.0037% $ 10.3m | |
| Senior VP of Finance | 2.4yrs | sin datos | 0.00033% $ 914.2k | |
| Executive VP and Chief Information & Digital Officer | no data | sin datos | 0.0013% $ 3.5m | |
| Vice President of Investor Relations | 6.8yrs | sin datos | sin datos | |
| Executive Vice President of Strategic Access | less than a year | US$13.94m | 0.0024% $ 6.8m | |
| Executive VP & Chief Human Resources Officer | 2.1yrs | US$11.26m | 0.00025% $ 692.6k | |
| Executive VP & President of Merck Animal Health | 14.7yrs | US$9.10m | 0.0065% $ 18.0m | |
| Executive VP and President of Oncology & MSD International | 5.3yrs | sin datos | 0.00086% $ 2.4m |
5.3yrs
Permanencia media
58yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MRK es experimentado (5.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 4.8yrs | US$20.80m | 0.018% $ 49.8m | |
| Independent Director | 10.7yrs | US$405.00k | 0.000070% $ 193.9k | |
| Independent Director | 30.7yrs | US$365.00k | 0.00053% $ 1.5m | |
| Independent Lead Director | 18.5yrs | US$415.00k | 0.00021% $ 581.7k | |
| Independent Director | 6yrs | US$340.00k | 0.000040% $ 110.8k | |
| Independent Director | 4yrs | US$350.00k | 0.00065% $ 1.8m | |
| Independent Director | 8.2yrs | US$340.00k | 0.00012% $ 332.4k | |
| Independent Director | 5.2yrs | US$350.00k | 0% $ 0 | |
| Independent Director | 6.2yrs | US$340.00k | 0.000020% $ 55.4k | |
| Independent Director | 6.2yrs | US$385.00k | 0% $ 0 | |
| Independent Director | 10.7yrs | US$405.00k | 0% $ 0 | |
| Independent Director | 7.2yrs | US$340.00k | 0% $ 0 |
6.7yrs
Permanencia media
66.5yo
Promedio de edad
Junta con experiencia: La junta directiva de MRK se considera experimentada (6.7 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/03 01:09 |
| Precio de las acciones al final del día | 2026/05/01 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Merck & Co., Inc. está cubierta por 50 analistas. 22 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Charles Butler | Barclays |